Endo International and Par Pharmaceutical Holdings have entered into a definitive agreement under which Endo will acquire Par for $8.1 billion. The combination will create a leading specialty pharmaceutical company with a generics business that is one of the industry’s fastest growing and among the top five as measured by U.S. sales. “Our generics business, Qualitest, continues to be an extremely attractive and effective growth driver for Endo. This transaction with Par builds upon our generics...